Haemonetics Corporation
05/25/2022 | Press release | Distributed by Public on 05/25/2022 04:15
Management Change/Compensation - Form 8-K
hae-20220520
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2022
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 001-14041 | 04-2882273 |
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number) |
(I.R.S. Employer
Identification No.)
|
125 Summer Street
Boston, MA02110
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: | ||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $.01 par value per share | HAE | New York Stock Exchange |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
|
Emerging Growth Company
|
| ☐ |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
Dan Goldstein, Vice President, Corporate Controller and Principal Accounting Officer will leave Haemonetics Corporation (the "Company") on August 9, 2022. The Company is grateful for Mr. Goldstein's meaningful contributions during his time at the Company. Mr. Goldstein will remain in his current role while the Company conducts a search for his successor.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||
| Date: May 25, 2022 | By: | /s/ Christopher A. Simon |
| Name: | Christopher A. Simon | |
| Title: | President and Chief Executive Officer | |